



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

## Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 06, 2020 1:00 - 5:00 PM

Via Zoom webinar

### MEETING MINUTES

---

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333**

**Members Present:** Mark Helm, MD, MBA, FAAP; Caryn Mickelson, PharmD; Russell Huffman, DNP, PMHNP; William Origer, MD, James Slater, PharmD; Patrick DeMartino, MD; Stacy Ramirez, PharmD; Cathy Zehrung RPh; Jim Rickards, MD, MBA

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Megan Herink, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Dee Weston, JD; Brandon Wells; Jennifer Bowen

**Audience:** Aimee Weems, Acorda Therapeutics Inc; Amy Burns, AllCare CCO; Andrea Wilcuts, Takeda; **Anthony Wheeler, Eli Lilly\***; Baylee Mayfield Salud Inter/OSU intern; Bill McDougall, Biogen; Bruce Wallace, Azurity; Camille Kerr, Regeneron; Carmen Oliver, Biohaven; **Carrie Johnson, Amgen\***; **Chelsea Leroue, Biohaven\***; Chi Kohlhoff, Viela Bio; Chris DeSimone, Akcea Therapeutics; Daksha Bogdon GNE; Dan Allen, Sanofi-Genzyme; Dave Beecham, Amgen; David Large, Biohaven; Dennis Schaffner, Sanofi Genzyme; Deron Grothe, Teva; Danielle Shannon, WVP Health; Emma Selm; Garth Wright, Genentech; **Herbert Alexander Krob, MD\***; Hiten Patadia, Otsuka; **Ian D'Souza Intra-Cellular Therapies Inc\***; Jean Harris; Novo Nordisk Inc; Jean Ritter, Zealand Pharm; John Sekab, Akcea Therapeutics; **Julie Baker, Deciphera Pharmaceuticals\***; Katie Scheelar, EOCCO/Moda Helath; Kelly Wright, Immunomedics NAD; **Jennifer Shear, Teva Pharmaceuticals\***; Lisa Dunn, Amgen; Lori Howarth, Bayer; Lori McDermott, Supernus; **Lynda Finch, Biogen\***; **Mae Kwong, Janssen\***; Margaret Olmon, Abbvie; Mark Duerre, Intra-Cellular Therapies Inc; Mark Friedrich; Mark Kantor, Allcare; Melissa Bailey-Hall, Eli Lilly; Michael Foster, BMS; Nichole Robling, Ostuka; Paul Thompson, Alkermes; Rick Frees, Vertex; Robin Traver, Umpqua Health; Roy Lindfield, Sunvion Pharmaceuticals; Sarah Day, Redhill Biopharma; Shirley

Quach, Norvartis; Stacy Finkebeiner, Teva; Stephanie Lattig, Novo Nordisk; Suzanne Gauen, Providence Health Plans; Tiffany Jones, Pacific Source; Trent Taylor, J & J; Wendy Bibeau, BMS; **Wendy Borgersen, RedHill Biopharma\***

**(\*) Provided verbal testimony**

**Written testimony:** Posted to OSU Website

---

**I. CALL TO ORDER**

- A. The meeting was called to order at approximately 1:05 pm. Introductions were made by Committee members and staff
- B. Conflict of Interest Declaration - No new conflicts of interest were declared
- C. Approval of June 2020 minutes presented by Mr. Citron  
**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
- D. Department Update provided by Dee Weston

---

**II. CONSENT AGENDA TOPICS**

- A. Quarterly Utilization Reports
- B. Antipsychotic Class Update with Caplyta™ (lumateperone) New Drug Evaluation (NDE)
- C. Vascular Endothelial Growth Factors (VEGF) Class Update with Beovu® (Brolucizumab-dbll) NDE
- D. ADHD Literature Scan
- E. Immune Globulin Drug Use Evaluation (DUE)
- F. Oncology Policy Update
- G. Orphan Drug Policy Update
  - 1. Public Comment**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

**III. DUR ACTIVITIES**

- A. ProDUR Report - Mr. Holsapple presented the ProDUR report
- B. RetroDUR Report – Dr. Engen presented the RetroDUR Report
- C. Oregon State Drug Reviews
  - 1. Biosimilar Medications: Key Considerations Providers
  - 2. Coronavirus management: Evidence for Treatment and Drug Shortage UpdatesDr. Sentena presented two recently published newsletters, thanked the Committee for reviewing the draft versions and solicited ideas for future newsletters

---

#### IV. PREFERRED DRUG LIST NEW BUSINESS

A. Cardiovascular Outcomes of Newer Diabetes Drugs DERP Summary

Dr. Sentena presented the proposal to:

1. Remove the requirement for step therapy - other than metformin - for DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors
2. Evaluate comparative costs in executive session

**ACTION:** The Committee amended question #7 in the SGLT-2 Inhibitor criteria to approve for 12 months

**Motion to approve, 2<sup>nd</sup>, all in favor**

B. Non-statin Drugs for Dyslipidemia Class Update

Dr. Herink presented the proposal to:

1. Maintain Nexletol™ (bempedoic acid) and Nexlizet™ (bempedoic acid/ezetimibe) as non-preferred
2. Implement proposed Bempedoic Acid PA criteria
3. Update Omega-3 Fatty Acid PA criteria to include new FDA approved indication for icosapent ethyl
4. Evaluate comparative costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

C. Multiple Sclerosis DERP Summary

Dr. Moretz presented the proposal to:

1. Revise the Oral Multiple Sclerosis Drugs PA criteria to include newly approved drugs - monomethyl fumarate, diroximel fumarate, ozanimod, cladribine, and siponimod – and to add safety monitoring metrics, and the same renewal criteria outlined in Ocrelizumab criteria
2. Revise the Natalizumab PA criteria to reflect the expanded indication for all forms of relapsing MS: clinically isolated syndrome; relapsing-remitting multiple sclerosis; and secondary progressive multiple sclerosis
3. Evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

D. Serotonin Agonists (formerly Triptans) Class Update

Dr. Sentena presented the proposal to:

1. Rename the Triptan class Serotonin Agonists
2. Evaluate comparative costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

E. Calcitonin Gene-Related Peptide (CGRP) Inhibitors DERP Summary

Dr. Sentena presented the proposal to:

1. Update the CGRP Antagonists PA criteria to include acute migraine treatments - rimegepant and ubrogepant - and the expanded indication for cluster headache prevention for galcanezumab
2. Evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

F. Topical Analgesics and Anesthetics Class Update

Dr. Moretz presented the proposal to:

1. Rename the topical analgesic class as “topical pain medications” and add topical anesthetics to this new PDL class
2. Designate at least one topical anesthetic with an indication for a funded condition on the HERC prioritized list as a preferred agent based on cost
3. Add class to PDL and evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

## V. EXECUTIVE SESSION

**Members Present:** Mark Helm, MD, MBA, FAAP; Caryn Mickelson, PharmD; Russell Huffman, DNP, PMHNP; William Origer, MD, James Slater, PharmD; Patrick DeMartino, MD, MPh; Stacy Ramirez, PharmD; Cathy Zehrung RPh; Jim Rickards, MD, MBA

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Megan Herink, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Dee Weston, JD; Brandon Wells; Jennifer Bowen

---

## VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. Antipsychotic Class Update

**Recommendation:** Make Abilify® (aripiprazole tablets) and Geodon® (ziprasidone capsules) and their generic alternatives preferred

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

B. VEGF Class Update

**Recommendation:** make no changes to the PMPDP

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

C. ADHD literature scan:

**Recommendation:** Make Vyvanse® (lisdexamphetamine) chewable tablets preferred

**ACTION:** Motion to approve, 2<sup>nd</sup>, 7 in-favor, 2 opposed

D. Cardiovascular Outcomes of Newer Diabetes Drug DERP Summary:

**Recommendation:** Make Onglyza® (saxagliptin HCl), Trulicity® (dulaglutide), Farxiga® (dapagliflozin propanediol), Jardiance® (empagliflozin) and Invokana® (canagliflozin) preferred

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

E. Non-statin Drugs for Dyslipidemia Class Update

**Recommendation:** Make generic omega-3 fatty acids preferred and to no longer require clinical PA criteria based on that decision; and to make Triglide™/Tricor® (fenofibrate nanocrystalized tablets), Antara® (fenofibrate micronized capsules), Trilipix® (choline fenofibrate capsules) and their generic alternatives preferred

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

F. Multiple Sclerosis DERP Summary

**Recommendation:** make no changes to the PMPDP

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

G. Serotonin Agonists Class Update

**Recommendation:** Make Tosymra® (sumatriptan nasal spray) non-preferred

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

H. CGRP inhibitors

**Recommendation:** Make Emgality® (galcanezumab-gnlm) preferred but still subject to clinical PA criteria

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

I. Topical Analgesics and Anesthetics

**Recommendation:** Make lidocaine-prilocaine cream, diclofenac gel, viscous lidocaine, lidocaine cream, solution and jelly w/applicator preferred; and to make everything else non-preferred

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

---

## IX. ADJOURN

---

## X. OHA Rules Advisory Committee